Literature DB >> 7933084

A partially attenuated simian immunodeficiency virus induces host immunity that correlates with resistance to pathogenic virus challenge.

B L Lohman1, M B McChesney, C J Miller, E McGowan, S M Joye, K K Van Rompay, E Reay, L Antipa, N C Pedersen, M L Marthas.   

Abstract

Three infectious, attenuated molecular clones of simian immunodeficiency virus (SIVmac) were tested for viral and host determinants of protective immunity. The viruses differed in degree of virulence from highly attenuated to moderately attenuated to partially attenuated. Levels of immune stimulation and antiviral immunity were measured in rhesus macaques inoculated 2 years previously with these viruses. Monkeys infected with the highly attenuated or moderately attenuated viruses had minimal lymphoid hyperplasia, normal CD4/CD8 ratios, low levels of SIV-specific antibodies, and cytotoxic T-lymphocyte activity against p55gag (Gag) or gp160env (Env). Monkeys infected with the partially attenuated virus had moderate to marked lymphoid hyperplasia, normal CD4/CD8 ratios, high levels of SIV-specific antibodies, and cytotoxic T-lymphocyte activity against both Gag and Env. After pathogenic virus challenge, monkeys immunized with the partially attenuated virus had 100- to 1,000-fold-lower viral load in peripheral blood mononuclear cells and lymph node mononuclear cells than naive control animals. One of four monkeys immunized with the highly attenuated virus and two of four monkeys immunized with the moderately attenuated virus developed similarly low viral loads after challenge. These three attenuated strains of SIV induced a spectrum of antiviral immunity that was inversely associated with their degree of attenuation. Only the least attenuated virus induced resistance to challenge infection in all immunized monkeys.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7933084      PMCID: PMC237139     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  32 in total

Review 1.  Virus-induced immunosuppression: infections with measles virus and human immunodeficiency virus.

Authors:  M B McChesney; M B Oldstone
Journal:  Adv Immunol       Date:  1989       Impact factor: 3.543

Review 2.  Human immunodeficiency virus: an agent that defies vaccination.

Authors:  N Nathanson; F Gonzalez-Scarano
Journal:  Adv Vet Sci Comp Med       Date:  1989

Review 3.  The lentiviruses: maedi/visna, caprine arthritis-encephalitis, and equine infectious anemia.

Authors:  W P Cheevers; T C McGuire
Journal:  Adv Virus Res       Date:  1988       Impact factor: 9.937

4.  IL-4 (B cell-stimulatory factor 1) regulates multiple aspects of influenza virus-specific cell-mediated immunity.

Authors:  D W Horohov; J A Crim; P L Smith; J P Siegel
Journal:  J Immunol       Date:  1988-12-15       Impact factor: 5.422

5.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

6.  Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids.

Authors:  R D Salter; D N Howell; P Cresswell
Journal:  Immunogenetics       Date:  1985       Impact factor: 2.846

7.  Cellular localization of simian immunodeficiency virus in lymphoid tissues. I. Immunohistochemistry and electron microscopy.

Authors:  D J Ringler; M S Wyand; D G Walsh; J J MacKey; L V Chalifoux; M Popovic; A A Minassian; P K Sehgal; M D Daniel; R C Desrosiers
Journal:  Am J Pathol       Date:  1989-02       Impact factor: 4.307

Review 8.  Animal virus infections that defy vaccination: equine infectious anemia, caprine arthritis-encephalitis, maedi-visna, and feline infectious peritonitis.

Authors:  N C Pedersen
Journal:  Adv Vet Sci Comp Med       Date:  1989

9.  Efficacy of live-attenuated and whole-inactivated simian immunodeficiency virus vaccines against vaginal challenge with virulent SIV.

Authors:  M L Marthas; C J Miller; S Sutjipto; J Higgins; J Torten; B L Lohman; R E Unger; R A Ramos; H Kiyono; J R McGhee
Journal:  J Med Primatol       Date:  1992 Feb-May       Impact factor: 0.667

10.  Human immunodeficiency virus-specific cytotoxic responses of seropositive individuals: distinct types of effector cells mediate killing of targets expressing gag and env proteins.

Authors:  Y Riviere; F Tanneau-Salvadori; A Regnault; O Lopez; P Sansonetti; B Guy; M P Kieny; J J Fournel; L Montagnier
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

View more
  53 in total

1.  Immunization with a live, attenuated simian immunodeficiency virus vaccine leads to restriction of viral diversity in Rhesus macaques not protected from pathogenic challenge.

Authors:  D L Sodora; K E Sheridan; P A Marx; R I Connor
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

2.  Live, attenuated simian immunodeficiency virus SIVmac-M4, with point mutations in the Env transmembrane protein intracytoplasmic domain, provides partial protection from mucosal challenge with pathogenic SIVmac251.

Authors:  Barbara L Shacklett; Karen E S Shaw; Lou A Adamson; David T Wilkens; Catherine A Cox; David C Montefiori; Murray B Gardner; Pierre Sonigo; Paul A Luciw
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

3.  In vitro evolution of a highly replicating, doxycycline-dependent HIV for applications in vaccine studies.

Authors:  G Marzio; K Verhoef; M Vink; B Berkhout
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

4.  An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge.

Authors:  S L Buge; E Richardson; S Alipanah; P Markham; S Cheng; N Kalyan; C J Miller; M Lubeck; S Udem; J Eldridge; M Robert-Guroff
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

5.  Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus.

Authors:  R Shibata; C Siemon; S C Czajak; R C Desrosiers; M A Martin
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

6.  Construction of a doxycycline-dependent simian immunodeficiency virus reveals a nontranscriptional function of tat in viral replication.

Authors:  Atze T Das; Bep Klaver; Alex Harwig; Monique Vink; Marcel Ooms; Mireille Centlivre; Ben Berkhout
Journal:  J Virol       Date:  2007-08-01       Impact factor: 5.103

7.  Induction of vigorous cytotoxic T-lymphocyte responses by live attenuated simian immunodeficiency virus.

Authors:  R P Johnson; R L Glickman; J Q Yang; A Kaur; J T Dion; M J Mulligan; R C Desrosiers
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

8.  AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: protection from an intraclade challenge administered systemically or mucosally by an attenuated vaccine.

Authors:  Mauro Pistello; Donatella Matteucci; Francesca Bonci; Patrizia Isola; Paola Mazzetti; Lucia Zaccaro; Antonio Merico; Daniela Del Mauro; Norman Flynn; Mauro Bendinelli
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

9.  Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus.

Authors:  J E Clements; R C Montelaro; M C Zink; A M Amedee; S Miller; A M Trichel; B Jagerski; D Hauer; L N Martin; R P Bohm
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

10.  Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara.

Authors:  V M Hirsch; T R Fuerst; G Sutter; M W Carroll; L C Yang; S Goldstein; M Piatak; W R Elkins; W G Alvord; D C Montefiori; B Moss; J D Lifson
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.